Keros Therapeutics (KROS) Gets a Buy from Oppenheimer

Tip Ranks
2025.11.12 12:56
portai
I'm PortAI, I can summarize articles.

Oppenheimer analyst Andreas Argyrides has maintained a Buy rating on Keros Therapeutics (KROS) with a price target of $27.00. Argyrides, who focuses on the Healthcare sector, has an average return of 13.1% and a 46.59% success rate on his recommendations. Additionally, Wells Fargo's Benjamin Burnett also issued a Buy rating for Keros, while Wedbush maintained a Hold rating on November 6.

Oppenheimer analyst Andreas Argyrides maintained a Buy rating on Keros Therapeutics today and set a price target of $27.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Argyrides covers the Healthcare sector, focusing on stocks such as Larimar Therapeutics, MoonLake Immunotherapeutics, and United Therapeutics. According to TipRanks, Argyrides has an average return of 13.1% and a 46.59% success rate on recommended stocks.

In addition to Oppenheimer, Keros Therapeutics also received a Buy from Wells Fargo’s Benjamin Burnett in a report issued yesterday. However, on November 6, Wedbush maintained a Hold rating on Keros Therapeutics (NASDAQ: KROS).

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer